Overview

Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

Status:
Recruiting

Trial end date:
2022-05-01

Target enrollment:

Participant gender:

Summary

A Phase 1a/1b, multicenter, open-label, non-randomized, dose-escalation, and cohort expansion study to examine the DLTs, MTD, and RP2D of SB 11285 administered as an IV infusion in patients with advanced solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

F-star Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.

Collaborator:

Precision For Medicine

Treatments:

Atezolizumab
Nivolumab